At the forefront of oncology

Ryvu Therapeutics discovers and develops small molecule therapies that address high value emerging targets in oncology.

Our pipeline is built from internally-discovered candidates which make use of diverse therapeutic mechanisms, including programs directed at targets in the areas of transcriptional regulation, synthetic lethality and immuno-oncology.

Publications

    • pdf file

      RVU120, a first-in-class CDK8 inhibitor for the treatment of relapsed/refractory AML and high-risk MDS: preliminary results from two ongoing studies.

      Download
    • pdf file

      Synergistic potential of RVU120, a first-in-class CDK8/CDK19 inhibitor, with venetoclax in AML: preclinical and initial clinical insights.

      Download
    • pdf file

      CDK8/19 Inhibition: A Promising Therapeutic Strategy in Myeloproliferative Neoplasms.

      Download
    • pdf file

      Preclinical candidate RVU305, an MTA-cooperative, brain-permeable PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatment

      Download
    • pdf file

      Discovery of novel synthetic lethal targets for effective and safe colorectal cancer therapies

      Download